Antitumor Efficacy of Interleukin 12-Transfected Mesenchymal Stem Cells in B16-F10 Mouse Melanoma Tumor Model
Pharmaceutics · 20.02.2025 · 17 (3) · 278
DOI: 10.3390/pharmaceutics17030278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.02.2025. Verfasst von Urška Kamenšek und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology, Institute of Oncology Ljubljana, SI-1000 Ljubljana, Slovenia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Slovenian Research and Innovation Agency, Institute of Oncology Ljubljana, Slovenian Research and Innovation Agency.
Abstract (Originalsprache)
Background/Objectives: Mesenchymal stromal cells (MSCs) hold the potential for tumor-targeted gene delivery due to their ex vivo manipulability, low immunogenicity, scalability, and inherent tumor-homing properties. Despite the widespread use of viral vectors for MSC genetic modification, safety concerns have prompted interest in non-viral alternatives, such as gene electrotransfer (GET). This study aimed to optimize GET parameters for MSCs transfection, assess MSCs biodistribution after in vivo administration, and evaluate the therapeutic potential of interleukin-12 (IL-12)-modified MSCs in a mouse melanoma model.
Methods
Human MSCs were isolated from umbilical cords under ethically approved protocols. GET protocols were optimized using a fluorescent reporter gene to evaluate transfection efficiency and cell viability. MSC biodistribution was examined following intravenous and intratumoral injections in murine tumor models using luminescent reporter gene. The therapeutic efficacy of IL-12-modified MSCs was assessed in a syngeneic mouse melanoma model.
Results
Optimized GET protocols achieved a transfection efficiency of 80% and a cell viability of 90%. Biodistribution studies demonstrated effective tumor retention of MSCs following intratumoral injections, whereas intravenous administration resulted in predominant cell localization in the lungs. IL-12-modified MSCs injected intratumorally significantly inhibited tumor growth, delaying tumor progression by five days compared to controls.
Conclusions
Optimized GET conditions enabled high-efficiency, high-viability MSCs transfection, facilitating their use as effective vehicles for localized cytokine delivery. While the innate tumor tropism of MSCs was not conclusively demonstrated, the study highlights the potential of GET as a reliable non-viral gene delivery platform and underscores the therapeutic promise of IL-12-modified MSCs in tumor-targeted gene therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental Oncology, Institute of Oncology Ljubljana, SI-1000 Ljubljana, Slovenia.
- Biotechnical Faculty, University of Ljubljana, SI-1000 Ljubljana, Slovenia.
- Faculty of Health Sciences, University of Primorska, SI-6310 Izola, Slovenia.
- Department for Therapeutic Services, Slovenian Institute for Transfusion Medicine, SI-1000 Ljubljana, Slovenia.
- Faculty of Pharmacy, University of Ljubljana, SI-1000 Ljubljana, Slovenia.
ORCID-Profile: Urška Kamenšek, Tim Božič, Maja Čemažar, Urban Švajger
Förderung
- The Slovenian Research and Innovation Agency
- Institute of Oncology Ljubljana
- Slovenian Research and Innovation Agency
Zitieren
APA
Kamenšek, U., Božič, T., Čemažar, M., & Švajger, U. (2025). Antitumor Efficacy of Interleukin 12-Transfected Mesenchymal Stem Cells in B16-F10 Mouse Melanoma Tumor Model. Pharmaceutics, 17(3), 278. https://doi.org/10.3390/pharmaceutics17030278
Vancouver
Kamenšek U, Božič T, Čemažar M, Švajger U. Antitumor Efficacy of Interleukin 12-Transfected Mesenchymal Stem Cells in B16-F10 Mouse Melanoma Tumor Model. Pharmaceutics. 2025;17(3):278. doi:10.3390/pharmaceutics17030278
BibTeX
@article{Kamenek2025,
author = {Kamenšek, Urška and Božič, Tim and Čemažar, Maja and Švajger, Urban},
title = {Antitumor Efficacy of Interleukin 12-Transfected Mesenchymal Stem Cells in B16-F10 Mouse Melanoma Tumor Model},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {3},
pages = {278},
doi = {10.3390/pharmaceutics17030278}
}
EUVIMED